---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-004796"
form_type: "8-K"
ticker: "MTVA"
cik: "0001638287"
company_name: "MetaVia Inc."
filed_at: "2025-04-15T23:59:59+00:00"
generated_at: "2026-05-23T14:41:55.055103+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# MetaVia reports positive Phase 1 MAD data for DA-1726 obesity drug: 6.3% max weight loss, strong glucose control

## Summary
- Mean weight loss 4.3% (max 6.3%) at 32 mg dose on Day 26 (p=0.0005).
- Fasted glucose lowered by mean 5.3 mg/dL (max 18 mg/dL); waist circumference reduced mean 1.6 in (max 3.9 in).
- No SAEs or discontinuations; mild GI AEs transient, 83% of 32 mg cohort reported early satiety.
- Adding higher-dose cohorts to determine MTD; planning Phase 1 Part 3 in Wegovy early drop-out patients.
- Company cites balanced GLP-1/glucagon activation as potential best-in-class profile for safety and efficacy.

## SEC filing metadata
- accession: 0001558370-25-004796
- form_type: 8-K
- ticker: MTVA
- cik: 0001638287
- company_name: MetaVia Inc.
- filed_at: 2025-04-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1638287/000155837025004796/0001558370-25-004796-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1638287/000155837025004796/mtva-20250415x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-004796
- JSON: https://secwatch.observer/filing/0001558370-25-004796.json
- Plain text: https://secwatch.observer/filing/0001558370-25-004796.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.